Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
about
Clinical significance of T cell metabolic reprogramming in cancerThe immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpointsRole of the tumor microenvironment in mature B-cell lymphoid malignanciesNew developments in the pathology of malignant lymphoma: a review of the literature published from May 2015–September 2015Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewCatching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?Lower expression of PD-1 and PD-L1 in peripheral blood from patients with chronic ITP.The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphomaImmune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.Checkpoint inhibitors in hematological malignanciesDistinct phenotypic subpopulations of circulating CD4(+)CXCR5(+) follicular helper T cells in children with active IgA vasculitis.Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis.Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix.Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patientsCo-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cellsPD-1 expression on the surface of peripheral blood CD4(+) T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma.PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.Prognostic value of PDL1 expression in pancreatic cancerExtranodal involvement in young patients with diffuse large B-cell lymphoma: distribution, prognostic value and treatment options.Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes.An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions.The emerging role of immune checkpoint inhibition in malignant lymphoma.Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders.PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.Targeting the programmed death-1 pathway in lymphoid neoplasms.Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.Cytotoxic response against Epstein Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment: clinical features and survival impact.Clinicopathological analysis of primary splenic diffuse large B-cell lymphoma.The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict OutcomePD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer.The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
P2860
Q26741974-02719CBA-9C1F-4031-9069-C5BE75FA566DQ26745842-721AEED0-FB77-46E0-828C-9F746578E843Q26748775-A859CCF2-F1D9-4009-A1FD-ED269B0FADB3Q26774077-DF84F10D-376A-4740-A035-B1880FBC0AD4Q27304386-80781445-F1C5-4671-A76A-1627BF181301Q28076071-E79C2B07-02E4-4A35-BF2C-E210D7F02100Q33431511-10EEE429-4EE9-4F53-9337-FE0CAC58F306Q33597192-E56CF560-D114-4A08-A24A-AA81891FCCE6Q33638083-80F87862-E93D-4AA6-AAFC-E53B38D45E12Q33651495-8A12823C-7DB0-4AF2-9380-9050220005B3Q36171178-08C9AAE1-CC07-463E-8893-AD5269B20989Q36358014-381A6C86-3C80-4B87-939E-D1D7C63F8DB8Q37061685-AC65092D-7C63-4D9E-87CE-ADC3F8ABE211Q37140496-94317071-B8AA-431A-B017-1A302BE233D5Q37362929-10401F85-E896-4DAC-BEE3-02838FE03966Q37429917-FB02C450-2FA9-4500-A459-667A032EEC95Q37644975-E64608F4-2C29-46E7-90C5-FE85C9D1E7ECQ37687595-AEC25DC8-5154-4260-B1CD-1C9A9CB2E2EEQ37697317-30BB4C70-3C06-44F5-8FD3-660A7AA0238AQ37706368-DFE08869-C84E-4373-8568-662EE132933BQ38749945-79725A34-DA42-49D3-B1E1-5886FF5E7B67Q38787346-E2F42377-C694-4E92-B0E0-623DDF99A452Q38791036-5BC8DDE1-17B2-4D49-8C52-ECF73EFA7118Q38844205-DE3EB265-4646-49DE-ADA0-CD351F9F7A9CQ38882112-05825FBB-A5D3-4B89-9B50-BCD827A6808CQ38996724-8E541268-15FE-48E6-A89B-8BE6DE2233D6Q39055861-DD155B15-3EBF-41DA-A4BD-CB8B5F26021EQ39102913-A3301AEB-CB7A-4514-814D-FD3A13BCC837Q39153358-3243219F-EB55-4779-A004-B3748601EBEEQ39237785-46D37615-C557-46A0-8069-3EF6006F165FQ39420466-A4694CDE-9748-4669-891C-E5CF3EA06324Q40052180-329FF7DD-C02F-4FEF-9290-5FA5BBF1B475Q40206016-23226B3C-ADCD-4D8A-AA85-72BA3C697FD3Q40649778-436649A6-6D11-4BF0-A4B4-E7FE4CD12735Q40975860-19122817-9101-4E4B-901F-F103794DF16DQ41069147-EFEE63D9-7EAD-48EE-830F-36BE698089A6Q41592956-77FE7525-C783-4A25-BD59-7C99A505D333Q41926342-7156191B-E526-4FBC-94A1-BEDF531CC1B8Q45325729-37A47647-68F0-4B72-BCCD-537165795EF3Q47093886-2F69F66B-56FF-4D5D-AD6A-28450315D569
P2860
Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Expression of programmed cell ...... diffuse large B-cell lymphoma.
@ast
Expression of programmed cell ...... diffuse large B-cell lymphoma.
@en
type
label
Expression of programmed cell ...... diffuse large B-cell lymphoma.
@ast
Expression of programmed cell ...... diffuse large B-cell lymphoma.
@en
prefLabel
Expression of programmed cell ...... diffuse large B-cell lymphoma.
@ast
Expression of programmed cell ...... diffuse large B-cell lymphoma.
@en
P2093
P2860
P1433
P1476
Expression of programmed cell ...... diffuse large B-cell lymphoma
@en
P2093
Ayako Ichikawa
Daisuke Niino
Fumiko Arakawa
Hiroaki Miyoshi
Ilseung Choi
Junichi Kiyasu
Koichi Akashi
Koichi Ohshima
Koji Nagafuji
Motoaki Shiratsuchi
P2860
P304
P356
10.1182/BLOOD-2015-02-629600
P407
P50
P577
2015-08-03T00:00:00Z